Elicio Therapeutics (ELTX) Operating Leases (2020 - 2026)

Elicio Therapeutics (ELTX) has 7 years of Operating Leases data on file, last reported at $3.8 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Leases fell 33.98% year-over-year to $3.8 million; the trailing twelve-month figure through Mar 2026 stood at $3.8 million (down 33.98% YoY), and the FY2025 full-year result was $4.1 million, down 19.8% from the prior year.
• Operating Leases for Q1 2026 stood at $3.8 million, down from $4.1 million in the prior quarter.
• Across five years, Operating Leases topped out at $7.4 million in Q2 2023 and bottomed at $297000.0 in Q1 2023.
• The 5-year median for Operating Leases is $5.3 million (2025), against an average of $4.8 million.
• The widest annual swing landed in 2023, when Operating Leases slumped 90.82%; it then jumped 1849.83% in 2024.
• A 5-year view of Operating Leases shows it stood at $6.8 million in 2022, then declined by 11.52% to $6.0 million in 2023, then fell by 15.02% to $5.1 million in 2024, then decreased by 19.8% to $4.1 million in 2025, then slipped by 6.62% to $3.8 million in 2026.
• The last three Operating Leases figures came in at $3.8 million (Q1 2026), $4.1 million (Q4 2025), and $5.3 million (Q3 2025), per Business Quant data.

Peer Comparison